PDE3A and glioblastoma: Additionally, we demonstrate the preclinical efficacy of BAY 2666605 and BRD3800 in glioblastomas with high expression of PDE3A and SLFN12 in vitro and in vivo, in both cellular and patient-derived glioblastoma models.